APHB - AmpliPhi Biosciences Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
4.4506
0.0000 (0.00%)
As of 3:59PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.3470
Open0.3470
Bid0.0000 x 1100
Ask0.3240 x 4000
Day's Range0.3086 - 0.3590
52 Week Range0.1500 - 3.7000
Volume4,650,991
Avg. Volume1,328,051
Market Cap148.957M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.
    PR Newswirelast month

    C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.

    MARINA DEL REY, Calif., May 9, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the previously-announced merger between C3J Therapeutics, Inc. ("C3J") and AmpliPhi Biosciences Corporation (NYSE American: APHB) ("AmpliPhi") has closed. The new combined company, known as Armata Pharmaceuticals, Inc., will focus on the development and advancement of phage-based therapeutic candidates to treat antibiotic-resistant infections.

  • Business Wirelast month

    AmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J Therapeutics

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that its stockholders voted to approve the proposals required to complete the business combination with C3J Therapeutics at a special meeting of AmpliPhi Biosciences stockholders held earlier today. Approximately 94% of the shares voted at the special stockholder meeting voted in favor of the transaction, with each of the other related proposals also receiving sufficient votes for approval. “Today’s resoundingly favorable shareholder vote clearly supports our combining of AmpliPhi and C3J Therapeutics to form a leading biopharmaceutical company focused on developing a promising portfolio of natural and synthetic phage therapies to treat serious and life-threatening antibiotic-resistant infections,” said Paul C. Grint, M.D., CEO of AmpliPhi Biosciences.

  • Business Wirelast month

    AmpliPhi Biosciences Reports First Quarter 2019 Financial Results and Business Highlights

    SAN DIEGO-- -- Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely targeted bacteriophage therapeutics $10.0 million of new capital to be invested in combined company Special shareholders meeting to be held on May 8, 2019 at 8:30 a.m. Pacific Time, transaction expected to close soon afterwards AmpliPhi ...

  • PR Newswire2 months ago

    Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

    NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller  announces investigation into possible breach of fiduciary duties in connection with the sale of APHB ...

  • PR Newswire3 months ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

    NEW YORK , March 27, 2019 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • Business Wire3 months ago

    AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

    SAN DIEGO-- -- Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmaceuticals Preliminary Merger proxy filed with the SEC on March 25, 2019, transaction expected to close in ...

  • ACCESSWIRE5 months ago

    4 Healthcare Stocks To Watch On Friday (1/4/19)

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday. Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share.

  • Business Wire5 months ago

    AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

    AmpliPhi Biosciences Corporation (“AmpliPhi”) (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and C3J Therapeutics, Inc. (“C3J”), a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials, today announced that the companies have entered into a definitive agreement under which a wholly owned subsidiary of AmpliPhi will merge with C3J in an all-stock transaction, subject to shareholder approval. The consummation of the merger transaction will result in a combined company that has a diverse clinical-stage pipeline, including a Phase 1/2-ready natural phage candidate targeting bacteremia, as well as a synthetic phage candidate targeting respiratory infections poised to enter Phase 1 development later this year.

  • Business Wire6 months ago

    AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

    AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced a 10-fold increase in yield from its manufacturing process, the result of a continuous and ongoing effort to enhance manufacturing efficiencies for AB-SA01, the company’s clinical stage lead drug product candidate. AB-SA01 is a targeted bacteriophage therapeutic in clinical development for the treatment of serious and life-threatening S. aureus infections, including those that do not respond to antibiotic therapy.

  • Zacks Small Cap Research7 months ago

    APHB: Phase 2 Trial of AB-SA01 in Bacteremia to Initiate 1H19…

    On October 8, 2018, AmpliPhi Biosciences Corp. (APHB) announced the presentation of data on the company’s expanded access program for AB-SA01 at IDWeek 2018. The presentation “Adjunctive bacteriophage therapy for sever Staphylococcal sepsis” was given by Prof. Jonathan Iredell, Senior Staff Infectious Disease Physician at the Westmead Hospital in Sydney, Australia. Ten of those patients also had infective endocarditis, with five of them having prosthetic valve endocarditis.

  • GlobeNewswire7 months ago

    Analysis: Positioning to Benefit within Artisan Partners Asset Management, Gamco Investors, Eiger BioPharmaceuticals, Waddell & Reed Financial, AmpliPhi Biosciences, and Limbach — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • How Much Of AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Do Institutions Own?
    Simply Wall St.7 months ago

    How Much Of AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Do Institutions Own?

    The big shareholder groups in AmpliPhi Biosciences Corporation (NYSEMKT:APHB) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...

  • Business Wire7 months ago

    AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

    SAN DIEGO-- -- The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the company’s expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% treatment success at the end of therapy Raised gross proceeds of $6.8 million through an underwritten public offering ...

  • Business Wire8 months ago

    AmpliPhi Biosciences Announces Closing of Public Offering

    AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously announced underwritten public offering. AmpliPhi sold 17,000,000 shares of common stock, or pre-funded warrants in lieu thereof, including 462,500 shares sold pursuant to the partial exercise of the underwriter’s option to purchase additional shares, and common warrants to purchase 17,500,000 shares of common stock, including common warrants to purchase 962,500 shares sold pursuant to the underwriter’s partial exercise of its option to purchase additional common warrants.

  • Business Wire8 months ago

    AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

    AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), and common warrants to purchase up to an aggregate of 16,537,500 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.40 per share and accompanying common warrant.

  • Business Wire8 months ago

    AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

    SAN DIEGO-- -- 13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis 83% patients in the modified intent-to-treat population achieved treatment success at the ...

  • Zacks Small Cap Research9 months ago

    APHB: Continued Success for Expanded Access Program; Ready to Initiate Clinical Trials for AB-SA01…

    On September 17, 2018, AmpliPhi Biosciences Corp. (APHB) announced updated results from the company’s use of its lead bacteriophage product candidates AB-SA01 and AB-PA01 through the expanded access program. To date, a total of 21 patients with serious or life-threatening infections not responding to standard antibiotic treatments have been treated at seven hospitals.

  • Business Wire9 months ago

    AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

    SAN DIEGO-- -- Professor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 and AB-PA01 AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that clinical case series data from the company’s ...

  • Business Wire9 months ago

    AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration (FDA) regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.

  • Business Wire9 months ago

    AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company had a Type B Pre-IND meeting with the U.S. Food and Drug Administration (FDA) and has now received the meeting minutes. Based on the FDA’s feedback, AmpliPhi currently plans to initiate the first randomized clinical trial of its AB-SA01 bacteriophage therapy product candidate in early 2019.

  • Business Wire9 months ago

    AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced updated topline clinical results for its ongoing single-patient expanded access program. 84% of patients achieved treatment success (physician’s assessment) at the end of therapy, defined as complete resolution or significant improvement of baseline signs and symptoms.

  • Why You Need To Look At This Factor Before Buying AmpliPhi Biosciences Corporation (NYSEMKT:APHB)
    Simply Wall St.9 months ago

    Why You Need To Look At This Factor Before Buying AmpliPhi Biosciences Corporation (NYSEMKT:APHB)

    Anyone researching AmpliPhi Biosciences Corporation (NYSEMKT:APHB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.Read More...

  • Zacks Small Cap Research10 months ago

    APHB: Meeting with the FDA Soon to Establish Path Forward for AB-SA01 and AB-PA01…

    The company reported that a total of 19 patients with serious or life-threatening infections have been treated with either AB-SA01 or AB-PA01 at a total of seven hospitals. As the company had previously guided, the goal was to get data on approximately 20 patients and then approach the FDA to get guidance on a regulatory path forward and design of Phase 2 trials for AB-SA01 and AB-PA01. AmpliPhi will be meeting with the FDA in August and September 2018 to do just that.

  • Business Wire10 months ago

    AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights

    SAN DIEGO-- -- 19 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have been treated with AB-SA01 or AB-PA01 under single-patient expanded access program AmpliPhi has scheduled meetings with the FDA in August and September to discuss the regulatory path forward for AB-SA01 and AB-PA01 AmpliPhi Biosciences Corporation , a clinical-stage biotechnology ...